CAS : 110958-19-5 FASORACETAM with Factory Price

Description

Fasoracetam is a research chemical of the racetam family.^[3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder.^[2][4]

Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies.^[5] It is orally bioavailable and is excreted mostly unchanged via the urine.^[6]

Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.^[5][7]

Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder.^[5]Hakonarson started a company called neuroFix Therapeutics to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.^[7][8] neuroFix was acquired by Medgenics in 2015.^[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.^[9] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.

Packaging and transportation 

Packing: this product is double-packed: the inner layer is sealed with edible polythene plastic bags, and the outer packaging is in cardboard boxes.The net content of each case is 25kg. It can also be packed according to customers' needs.

Transportation: light loading and unloading.Prevent the sun, rain, can not be mixed with toxic, harmful goods, this product is not dangerous goods, can be transported according to the general chemicals.
Storage: it should be stored in a dry, clean and dark environment. It is strictly prohibited to mix with toxic substances to avoid pollution.The shelf life is two years.


Packaging